Neuronetics (FRA:NRC) FCF Margin % : 6.17% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Neuronetics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Neuronetics's Free Cash Flow for the three months ended in Dec. 2023 was €1.15 Mil. Neuronetics's Revenue for the three months ended in Dec. 2023 was €18.63 Mil. Therefore, Neuronetics's FCF Margin % for the quarter that ended in Dec. 2023 was 6.17%.

As of today, Neuronetics's current FCF Yield % is -30.13%.

The historical rank and industry rank for Neuronetics's FCF Margin % or its related term are showing as below:

FRA:NRC' s FCF Margin % Range Over the Past 10 Years
Min: -59.13 Med: -49.09 Max: -25.9
Current: -48.5

During the past 8 years, the highest FCF Margin % of Neuronetics was -25.90%. The lowest was -59.13%. And the median was -49.09%.

FRA:NRC's FCF Margin % is ranked worse than
69.82% of 222 companies
in the Medical Diagnostics & Research industry
Industry Median: -10.405 vs FRA:NRC: -48.50

Neuronetics FCF Margin % Historical Data

The historical data trend for Neuronetics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics FCF Margin % Chart

Neuronetics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-49.95

-59.13

-54.84

-52.16

-48.22

Neuronetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-19.80	-99.41	-54.17	-59.69	6.17

Competitive Comparison of Neuronetics's FCF Margin %

For the Diagnostics & Research subindustry, Neuronetics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuronetics's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Neuronetics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Neuronetics's FCF Margin % falls into.

Neuronetics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Neuronetics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-31.551	/	65.426
	=	-48.22 %

Neuronetics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	1.15	/	18.628
	=	6.17 %

Neuronetics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Neuronetics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuronetics (FRA:NRC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neuronetics Inc (FRA:NRC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

STIM:USA NRC:Germany

Address

3222 Phoenixville Pike, Malvern, PA, USA, 19355

Website

https://www.neurostar.com

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.